Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals

PLoS One. 2020 Jan 10;15(1):e0227188. doi: 10.1371/journal.pone.0227188. eCollection 2020.

Abstract

Several European countries have established criteria for prioritising initiation of treatment in patients infected with the hepatitis C virus (HCV) by grouping patients according to clinical characteristics. Based on neural network techniques, our objective was to identify those factors for HIV/HCV co-infected patients (to which clinicians have given careful consideration before treatment uptake) that have not being included among the prioritisation criteria. This study was based on the Spanish HERACLES cohort (NCT02511496) (April-September 2015, 2940 patients) and involved application of different neural network models with different basis functions (product-unit, sigmoid unit and radial basis function neural networks) for automatic classification of patients for treatment. An evolutionary algorithm was used to determine the architecture and estimate the coefficients of the model. This machine learning methodology found that radial basis neural networks provided a very simple model in terms of the number of patient characteristics to be considered by the classifier (in this case, six), returning a good overall classification accuracy of 0.767 and a minimum sensitivity (for the classification of the minority class, untreated patients) of 0.550. Finally, the area under the ROC curve was 0.802, which proved to be exceptional. The parsimony of the model makes it especially attractive, using just eight connections. The independent variable "recent PWID" is compulsory due to its importance. The simplicity of the model means that it is possible to analyse the relationship between patient characteristics and the probability of belonging to the treated group.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS-Related Opportunistic Infections / complications*
  • AIDS-Related Opportunistic Infections / drug therapy*
  • Adolescent
  • Adult
  • Aged
  • Antiviral Agents / therapeutic use*
  • Coinfection
  • Decision Support Techniques
  • Female
  • Follow-Up Studies
  • HIV / genetics
  • Hepacivirus / genetics
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy*
  • Humans
  • Machine Learning*
  • Male
  • Middle Aged
  • Neural Networks, Computer
  • Prospective Studies
  • Spain
  • Young Adult

Substances

  • Antiviral Agents

Associated data

  • ClinicalTrials.gov/NCT02511496

Grants and funding

DGR, JCF, PAG and CHM were supported by TIN2017-85887-C2-1-P - Spanish Ministry of Economy and Competitiveness (MINECO) and FEDER funds - NO DGR - FPU16/02128 - Spanish Ministry of Education and Science - NO DGR - PI15/01570 - Fundación de Investigación Biomédica de Córdoba - NO ARJ - CP18/00111 - Spanish Ministry of Science, Promotion and Universities – NO.